- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT05876923
Los efectos del ejercicio agudo y crónico en el fenotipo inmunológico de los pacientes con leucemia linfocítica crónica
This clinical trial studies the effect of short-term (acute) and long-term (chronic) exercise on immune characteristics and function (phenotype) of patients with indolent non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Most newly-diagnosed CLL patients have early-stage disease at the time of diagnosis and do not require treatment. Despite not needing therapy, these patients have significant immune dysfunction. This may lead to an increased risk of serious infections requiring hospitalization and an increased risk of secondary non-blood-based (hematologic) cancers. Increasing CLL patients overall physical fitness levels, through exercise during the observation stage, may provide a realistic approach means to increase survival, decrease treatment-related side effects, and improve immune function. Information learned from this study may help researchers determine whether a particular exercise regimen can be used to strengthen the immune system of indolent NHL and CLL patients, delay time to disease progression, assess the need for treatment, and assess infection rates.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
- Otro: Questionnaire Administration
- Procedimiento: Biospecimen Collection
- Otro: Electronic Health Record Review
- Otro: Best Practice
- Otro: Cardiopulmonary Exercise Testing
- Procedimiento: Dual X-ray Absorptiometry
- Procedimiento: Physical Examination
- Procedimiento: Spirometry
- Otro: Exercise Intervention
- Otro: Physical Performance Testing
Descripción detallada
PRIMARY OBJECTIVES:
I. Determine how circulating immune cell abundance and function (via cell counts & cytokine profile) of CLL patients respond to acute (single bout) maximal exercise and how this differs from the response observed in group of age-matched controls by monitoring cardiopulmonary parameters and mobilization of immune cell phenotypes.
II. Determine how circulating immune cell mobilization and function (cell counts & cytokine profile) of CLL patients respond to a 12-week semi-supervised training program of moderate to high intensity, aerobic based exercise.
III. Evaluate the effectiveness of 12-weeks of semi-supervised exercise training (ET) versus (vs.) usual care (UC) at reducing cancer-related side effects and improving quality of life (QOL) and physical fitness in individuals with indolent non-Hodgkin (NHL) lymphoma during or after treatment.
IV. Determine that extent to which 12-weeks of semi-supervised ET can modify circulating immune cell mobilization and immune function in individuals with indolent NHL during or after treatment compared to UC.
V. Development of a forward-chaining AI expert system using both manual and physiology derived feedback to optimize training results and compare its efficacy at reducing cancer-related side effects and improving quality of life (QOL) and physical fitness in individuals with indolent NHL and CLL to that of the semi-supervised ET.
OUTLINE: CLL patients and healthy participants are assigned to Aim 1. CLL patients who complete all Aim 1 activities are assigned to Aim 2. Patients with indolent NHL will be assigned to Aims 3 and 4.
AIM 1: Participants undergo measurement of height/weight and vital signs (blood pressure, temperature, heart and breathing rate), complete lung function testing (spirometry), undergo an exercise test (cardiopulmonary exercise testing [CPET]), and undergo collection of blood samples on study. Participants may also undergo dual X-ray absorptiometry (DEXA) scan on study.
AIM 2: CLL patients complete aerobic based training program on study. Patients then complete all Aim 1 activities again after completion of aerobic based training program.
AIMS 3-4: Indolent NHL patients undergo measurement of height/weight and vital signs (blood pressure, temperature, heart and breathing rate), complete lung function testing (spirometry), undergo an exercise test (CPET), and undergo collection of blood samples on study. Participants may also undergo DEXA scan on study. Patients undergo muscular strength and functional endurance measurements of hand grip strength, upper body power via weighted chest pass, and leg strength with the timed chair stand test and 6-minute walk test (6MWT). Patients are then randomized to 1 of 2 arms.
ARM I: Patients receive usual care on study.
ARM II: Patients complete aerobic based training program on study. Patients then complete all baseline activities again after completion of aerobic based training program.
AIM 5: All patients from Aims 3-4 will be invited to repeat Aims 3-4 baseline activities.
After completion of study intervention, patients are followed up every 6 months (Aims 2-4) or annually (Aim 5) for 3 years.
Tipo de estudio
Inscripción (Actual)
Fase
- No aplica
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Arizona
-
Scottsdale, Arizona, Estados Unidos, 85259
- Mayo Clinic in Arizona
-
-
Minnesota
-
Rochester, Minnesota, Estados Unidos, 55905
- Mayo Clinic in Rochester
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- English speaking
- Between the ages of 18-80
- Histologically confirmed diagnosis of indolent non-Hodgkin lymphoma (NHL) will be required to participate in Aim 2 (CLL/SLL only), aim 3 and 4 (indolent NHL) and aim 5 (indolent NHL) of this study
Exclusion Criteria:
- Healthy subjects participating in Aim 1 will be excluded if they have known cardiovascular or pulmonary disease (e.g. heart disease, coronary artery disease, chronic obstructive pulmonary disease [COPD], asthma, etc.) an orthopedic or musculoskeletal limitation which would limit ability to exercise or are a current or former smoker
- Indolent NHL individuals receiving treatment must have least 8 weeks of planned treatment remaining and those who have already received treatment must be at least 6 months post and have no planned treatments during the 12-week intervention period to be eligible. Individuals that are participating prior to receiving treatment must not have any scheduled treatments during their participation. Individuals will be excluded if they have uncontrolled hypertension, cardiac illness, or are not approved by their oncologist to participate
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Cuidados de apoyo
- Asignación: No aleatorizado
- Modelo Intervencionista: Asignación Secuencial
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Aim 1 (vitals, spirometry, CPET, blood samples, DEXA)
Participants undergo measurement of height/weight and vital signs (blood pressure, temperature, heart and breathing rate), complete lung function testing (spirometry), undergo an exercise test (CPET), and undergo collection of blood samples on study. Participants may also undergo DEXA scan on study. |
Ancillary studies Undergo collection of blood
Otros nombres:
Ancillary studies Undergo CPET
Otros nombres:
Undergo DEXA scan
Otros nombres:
Undergo measurement of height/weight and vital signs
Otros nombres:
Undergo spirometry |
|
Experimental: Aim 2 (aerobic based training program, Aim 1 activities)
CLL patients complete aerobic based training program on study. Patients then complete all Aim 1 activities again after completion of aerobic based training program. |
Ancillary studies Undergo collection of blood
Otros nombres:
Ancillary studies Undergo CPET
Otros nombres:
Undergo DEXA scan
Otros nombres:
Undergo measurement of height/weight and vital signs
Otros nombres:
Undergo spirometry Undergo aerobic based training program |
|
Comparador activo: Aims 3-4 arm I (indolent NHL usual care)
Indolent NHL patients undergo measurement of height/weight and vital signs (blood pressure, temperature, heart and breathing rate), complete lung function testing (spirometry), undergo an exercise test (CPET), and undergo collection of blood samples on study. Participants may also undergo DEXA scan on study. Patients undergo muscular strength and functional endurance measurements of hand grip strength, upper body power via weighted chest pass, and leg strength with the timed chair stand test and 6MWT. Patients receive usual care on study. |
Ancillary studies Undergo collection of blood
Otros nombres:
Ancillary studies Receive usual care
Otros nombres:
Undergo CPET
Otros nombres:
Undergo DEXA scan
Otros nombres:
Undergo measurement of height/weight and vital signs
Otros nombres:
Undergo spirometry Undergo muscular strength and functional endurance measurements
Otros nombres:
|
|
Comparador activo: Aims 3-4 arm II (indolent NHL aerobic based training program)
Indolent NHL patients undergo measurement of height/weight and vital signs (blood pressure, temperature, heart and breathing rate), complete lung function testing (spirometry), undergo an exercise test (CPET), and undergo collection of blood samples on study. Participants may also undergo DEXA scan on study. Patients undergo muscular strength and functional endurance measurements of hand grip strength, upper body power via weighted chest pass, and leg strength with the timed chair stand test and 6MWT. Patients complete aerobic based training program on study. Patients then complete all baseline activities again after completion of aerobic based training program. |
Ancillary studies Undergo collection of blood
Otros nombres:
Ancillary studies Receive usual care
Otros nombres:
Undergo CPET
Otros nombres:
Undergo DEXA scan
Otros nombres:
Undergo measurement of height/weight and vital signs
Otros nombres:
Undergo spirometry Undergo aerobic based training program Undergo muscular strength and functional endurance measurements
Otros nombres:
|
|
Experimental: Aim 5 (repeat baseline activities)
All patients from Aims 3-4 will be invited to repeat Aims 3-4 baseline activities. |
Ancillary studies Undergo collection of blood
Otros nombres:
Ancillary studies Undergo CPET
Otros nombres:
Undergo DEXA scan
Otros nombres:
Undergo measurement of height/weight and vital signs
Otros nombres:
Undergo spirometry Undergo muscular strength and functional endurance measurements
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Assess circulating immune cell abundance and function pre-intervention
Periodo de tiempo: Baseline
|
A standardized questionnaire will be administered to assess levels of past and current physical activity. Baseline measurement of pulmonary function (PFT) will be collected and possibly a body composition scan via dual x-ray absorptiometry (DEXA). While subjects perform cardiopulmonary exercise testing (CPET), cardiopulmonary vitals will be assessed and monitored throughout exercise and in recovery. A 40 mL venous blood sample will be drawn at baseline and post exercise (80 mL total), along with finger prick measures of blood lactate at rest and early recovery. Blood samples will be evaluated to determine how circulating immune cell abundance and function (via cell counts & cytokine profile) of chronic lymphocytic leukemia (CLL) patients respond to acute (single bout) maximal exercise and how this differs from the response observed in group of age-matched controls by monitoring cardiopulmonary parameters and mobilization of immune cell phenotypes. |
Baseline
|
|
Assess circulating immune cell mobilization and function post-intervention
Periodo de tiempo: 12 weeks (at end of 12-week intervention)
|
Each subject will participate in a 12-weeks exercise program (3 times per week) at a moderate to high exercise intensity level based upon the results of their cardiopulmonary exercise testing (CPET). Upon completion of the program, subjects will return to the laboratory for post testing using the same techniques as used during the baseline. Venous blood samples drawn at rest after the program will be used to determine how circulating immune cell mobilization and function (cell counts and cytokine profile) of CLL patients respond to intervention. Usual descriptive statistics will be performed - means, standard deviations, and ranges. Comparisons within a group over time or pre/post will be performed using paired t-tests, while comparisons between groups will be performed using unpaired t-tests or where necessary using ANOVA. Comparisons will be made based on absolute values as well as changes during a test. |
12 weeks (at end of 12-week intervention)
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Assess circulating immune cell mobilization and function in follow-up
Periodo de tiempo: Annually up to 3 years
|
Each subject will participate in a 12-weeks exercise program (3 times per week) at a moderate to high exercise intensity level based upon the results of their cardiopulmonary exercise testing (CPET). Upon completion of the program, subjects will return to the laboratory for post testing using the same techniques as used during the baseline. Venous blood samples drawn at rest after the program will be used to determine how circulating immune cell mobilization and function (cell counts and cytokine profile) of CLL patients respond to intervention. Usual descriptive statistics will be performed - means, standard deviations, and ranges. Comparisons within a group over time or pre/post will be performed using paired t-tests, while comparisons between groups will be performed using unpaired t-tests or where necessary using ANOVA. Comparisons will be made based on absolute values as well as changes during a test. |
Annually up to 3 years
|
|
Fatigue - SCFS (indolent NHL only)
Periodo de tiempo: Baseline; 12 weeks (at end of 12-week intervention); every 6 months up to 3 years
|
The Schwartz Cancer Fatigue Scale (SCFS) is a 6-item instrument measuring physical and perceptual dimensions of fatigue experienced over the past 2 to 3 days. Each item is scored on a 5-point scale from 1 (not at all) to 5 (extremely) with scores ranging from 6 to 36. Higher scores indicate greater perception of fatigue. |
Baseline; 12 weeks (at end of 12-week intervention); every 6 months up to 3 years
|
|
Fatigue - FACIT-F (indolent NHL only)
Periodo de tiempo: Baseline; 12 weeks (at end of 12-week intervention); every 6 months up to 3 years
|
The Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) is a 13-item questionnaire used to measure fatigue levels and impact of fatigue on daily activities over the past 7 days. Each item is scored on a 5-point scale from 0 (not at all) to 4 (very much). total scores range from 0 to 52 with higher scores indicating lower level of fatigue. |
Baseline; 12 weeks (at end of 12-week intervention); every 6 months up to 3 years
|
|
Quality of Life - EORTC-QLQ-C30 (indolent NHL only)
Periodo de tiempo: Baseline; 12 weeks (at end of 12-week intervention); every 6 months up to 3 years
|
The European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-C30 is a 30-item questionnaire a questionnaire used to assess the quality of life of cancer patients. Twenty-eight questions are answered on a scale of 1-4 (1=not at all, 2=a little, 3=quite a bit, and 4= very much), and two questions are answered on a scale of 1-7 (1= very poor and 7=excellent). Higher summary scores indicate better health related quality of life. |
Baseline; 12 weeks (at end of 12-week intervention); every 6 months up to 3 years
|
|
Physical Activity - GPAQ (indolent NHL only)
Periodo de tiempo: Baseline; 12 weeks (at end of 12-week intervention); every 6 months up to 3 years
|
The Global Physical Activity Questionnaire (GPAQ) is a 16-item survey used to measure physical activity levels and sedentary behavior over the past week. Participants record different types and duration of physical activity in a typical week. Overall responses is scored by calculating Metabolic Equivalent of Task (MET) minutes and classifying physical activity levels as low, moderate, or high based on World Health Organization (WHO) guidelines. |
Baseline; 12 weeks (at end of 12-week intervention); every 6 months up to 3 years
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Michael P. Gustafson, PhD, Mayo Clinic
Publicaciones y enlaces útiles
Enlaces Útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Procesos Patológicos
- Neoplasias
- Enfermedad crónica
- Atributos de la enfermedad
- Enfermedades del sistema inmunológico
- Neoplasias por tipo histológico
- Enfermedades hematológicas
- Enfermedades linfáticas
- Trastornos linfoproliferativos
- Trastornos inmunoproliferativos
- Leucemia de células B
- Leucemia Linfoide
- Leucemia
- Condiciones Patológicas, Signos y Síntomas
- Enfermedades hemic y linfáticas
- Leucemia Linfocítica Crónica De Células B
- Administración de Servicios de Salud
- Calidad, acceso y evaluación de la atención médica
- Fenómenos fisiológicos musculoesqueléticos
- Fenómenos fisiológicos musculoesqueléticos y neuronales
- Técnicas de investigación
- Terapéutica
- Técnicas de laboratorio clínico
- Técnicas y procedimientos de diagnóstico
- Diagnóstico
- Calidad de la atención médica
- Indicadores de calidad, atención médica
- Imágenes de diagnóstico
- Técnicas de química, analítica
- Técnicas de diagnóstico, sistema respiratorio
- Técnicas de diagnóstico, cardiovascular
- Control de comportamiento
- Inmovilización
- Pautas como tema
- Garantía de calidad, atención médica
- Radiografía
- Pruebas de funciones cardíacas
- Pruebas de funciones respiratorias
- Ergometría
- Densitometría
- Fotometría
- Estándar de cuidado
- Manejo de muestras
- Restricción, físico
- Directrices de práctica como tema
- Prueba de ejercicio
- Absorptiometría, fotón
- Densidad ósea
- Clostridium perfringens epsilon-toxin
Otros números de identificación del estudio
- 22-012246
- 22-012246 (Otro identificador: Mayo Clinic Institutional Review Board)
- NCI-2023-03210 (Identificador de registro: CTRP (Clinical Trial Reporting Program))
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .